Q-omics provides the consensus-scored RPS3AP15 profile across patient tissues and cancer cell-line models. RPS3AP15 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, RPS3AP15 is differentially expressed in 6, with the highest sampling consensus in LUSC. Additionally, RPS3AP15 RNA expression shows 6,770 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight THCA, LUSC, and TGCT as cancer lineages where RPS3AP15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS3AP15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS3AP15 survival associations across molecular data types. RPS3AP15 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS3AP15 RNA expression–survival associations across cancer types. High RPS3AP15 expression shows unfavorable associations in KIRC, KICH and BRCA, but favorable associations in THCA, CESC and KIRP. The THCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for RPS3AP15 RNA expression.
This table summarizes RPS3AP15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS3AP15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS3AP15 shows lower tumor expression in LUSC, BRCA, KIRC, HNSC, LUAD and KIRP. The LUSC box plot shows higher RPS3AP15 RNA expression in normal versus tumor tissue (log2 FC = −0.247, t-test p < 0.001).
This table shows molecular features associated with RPS3AP15 in patient tissues and cancer cell lines. In patient samples, RPS3AP15 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
